Patients with acute COPD exacerbations are seen frequently in the emergency department (ED). Acute exacerbations are associated with significant morbidity, mortality and health care expenditures.

Almost 16 million adults have COPD in the United States and about 3 in 4 people with this condition have at least one flare (exacerbation) a year, cites a review. But you don’t have to sit and wait ...

—A new study finds that some patients are proactive (they seek immediate treatment), while others tough it out (wishing to avoid the ‘hassle’ or ‘inconvenience’). What can clinicians do to better ...

Frequent productive cough was experienced by patients with asthma and/or chronic obstructive pulmonary disease (COPD), with symptom prevalence increasing with higher disease severity, according to the ...

Add Yahoo as a preferred source to see more of our stories on Google. Woman’s World has affiliate partnerships. We receive compensation when you click on a link and make a purchase. Learn more! Sure, ...

If you have chronic obstructive pulmonary disease (COPD), you’re probably no stranger to flares. These are sudden attacks where breathing and coughing symptoms get worse and stay that way. You could ...

This transcript has been edited for clarity. For more episodes, download the Medscape app or subscribe to the podcast on Apple Podcasts, Spotify, or your preferred podcast provider. Witt: I'm so glad ...

Emerging bronchoscopic therapies provide minimally invasive options for COPD, filling the gap between traditional and invasive treatments. Bronchoscopic lung volume reduction (BLVR) uses one-way ...

The FDA approved dupilumab (Dupixent) as the first biologic treatment for adults with chronic obstructive pulmonary disease (COPD), Sanofi and Regeneron announced on Friday. An injectable interleukin ...

Please provide your email address to receive an email when new articles are posted on . This analysis focused on adults with moderate to severe COPD without an exacerbation during the ENHANCE trials.

Treatment with Nucala, an interleukin-5 antagonist monoclonal antibody, significantly reduced exacerbations leading to hospitalizations and emergency department visits. The Food and Drug ...